化疗联合CIK输注对晚期NSCLC患者T细胞哑群及生存的影响

目的：探讨化疗联合细胞因子诱导的杀伤细胞（ cytokine induced killer ，CIK）治疗晚期非小细胞肺癌（ non small cell lung cancer，NSCLC）患者的近期疗效。方法将61例确诊的晚期非小细胞肺癌患者给予化疗联合CIK治疗，观察治疗前后外周血中T细胞亚群及细胞因子的变化和临床疗效，并观察其对1年总生存率和无进展生存期的影响。结果 CIK回输后患者CD3、CD8、CD56的比例较治疗前明显上调（P＜0．05），且CIK输注可明显提高患者Th1类细胞因子IFN-γ和TNF-α的水平（P＜0．05）。治疗总体有效率为47．3％，临床获益率为67．3％。该研究患者的中位总生存期为10．3个月，1年生存率为22．9％，而无进展生存期7．2个月，1年无进展生存为14．0％。结论化疗CIK治疗能提高患者的免疫功能及生活质量，有望成为非小细胞肺癌有效的过继免疫治疗方法。

Short-term effects of chemotherapy co-cultured with cytokine induced killer cells(CIK) on patients with advanced non small cell lung cancer(NSCLC)

Objective To investigate short-term effects of chemotherapy co-cultured with cytokine induced killer cells （CIK） on patients with advanced non small cell lung cancer （NSCLC）.Methods Sixty-one patients with advanced NSCLC were treated with chemothera-py combined with CIK therapy .T lymphocyte subsets and cytokines in peripheral blood of the patients were analyzed .Clinical effects and the adverse reactions were observed .Results The ratios of CD3,CD4,CD56 and CIM/CD8 increased after treatment,and the difference was statistically significant（P〈0.05）.The therapy increased IFN-γand TNF-αlevel（P〈0.05）.The total therapeutic effi-cacy and clinical benefit rate were 47.3%and 67.3%.Median PFS was 7.2 months and the PFS rate at 1 year 14%.Median OS was 10.3 months and the rate of OS at 1 year 22.9%.Conclusion CIK therapy can improve immune functions .It is likely to be an effec-tive adoptive immunotherapy for advanced non-small cell lung cancer .